文献速递其他结缔组织病

Semaphorin 4A在系统性硬化症中诱导炎症与纤维化

Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2019-08-27

该研究分析Semaphorin 4A(Sema4A)在系统性硬化症(SSc)炎症与纤维化中的作用。SSc患者血浆Sema4A及单核细胞和CD4+ T细胞Sema4A表达显著高于健康对照(P < 0.05)。Sema4A增强Th17细胞因子表达并诱导真皮成纤维细胞促纤维化表型,阻断其受体可消除该效应,提示Sema4A可能为SSc治疗新靶点。

要点

  • SSc患者血浆及单核细胞、CD4+ T细胞Sema4A表达显著升高(P < 0.05)。
  • Sema4A增强CD4+ T细胞Th17细胞因子表达(P < 0.05)。
  • Sema4A诱导真皮成纤维细胞促纤维化表型,阻断受体可消除。

核心结论

  • Sema4A在SSc中直接且双重促进炎症和纤维化,可能为新型治疗靶点。

研究设计与样本

  • 比较健康对照(n = 11)与SSc患者(n = 20)血浆Sema4A水平(ELISA)。
  • 检测健康对照与SSc患者(每组n = 6-7)单核细胞和CD4+ T细胞Sema4A及其受体表达(ELISA和流式细胞术)。
  • 分析CD4+ T细胞(n = 5-7)Th17细胞因子产生(ELISA和流式细胞术)。
  • 分析真皮成纤维细胞(n = 6)炎症介质和细胞外基质成分产生(定量PCR、ELISA、Western blot、共聚焦显微镜和ECM沉积实验)。

主要发现

  • SSc患者血浆Sema4A水平及循环单核细胞和CD4+ T细胞Sema4A表达显著高于健康对照(P < 0.05)。
  • 炎症介质显著上调SSc患者单核细胞和CD4+ T细胞分泌Sema4A(P < 0.05,与未刺激SSc细胞比较)。
  • Sema4A显著增强CD3/CD28诱导的总CD4+ T细胞及各CD4+ T细胞亚群Th17细胞因子表达(P < 0.05,与未刺激SSc细胞比较)。
  • Sema4A诱导健康对照和SSc患者真皮成纤维细胞促纤维化表型,阻断或沉默Sema4A受体表达可消除该效应。

临床怎么用

  • Sema4A可能作为SSc炎症和纤维化的生物标志物及治疗靶点,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the potential role of semaphorin 4A (Sema4A) in inflammatory and fibrotic processes involved in the pathology of systemic sclerosis (SSc). METHODS: Sema4A levels in the plasma of healthy controls (n = 11) and SSc patients (n = 20) were determined by enzyme-linked immunosorbent assay (ELISA). The expression of Sema4A and its receptors in monocytes and CD4+ T cells from healthy controls and SSc patients (n = 6-7 per group) was determined by ELISA and flow cytometry. Th17 cytokine production by CD4+ T cells (n = 5-7) was analyzed by ELISA and flow cytometry. The production of inflammatory mediators and extracellular matrix (ECM) components by dermal fibroblast cells (n = 6) was analyzed by quantitative polymerase chain reaction, ELISA, Western blotting, confocal microscopy, and ECM deposition assay. RESULTS: Plasma levels of Sema4A, and Sema4A expression by circulating monocytes and CD4+ T cells, were significantly higher in SSc patients than in healthy controls (P < 0.05). Inflammatory mediators significantly up-regulated the secretion of Sema4A by monocytes and CD4+ T cells from SSc patients (P < 0.05 versus unstimulated SSc cells). Functional assays showed that Sema4A significantly enhanced the expression of Th17 cytokines induced by CD3/CD28 in total CD4+ T cells as well in different CD4+ T cell subsets (P < 0.05 versus unstimulated SSc cells). Finally, Sema4A induced a profibrotic phenotype in dermal fibroblasts from both healthy controls and SSc patients, which was abrogated by blocking or silencing the expression of Sema4A receptors. CONCLUSION: Our findings indicate that Sema4A plays direct and dual roles in promoting inflammation and fibrosis, 2 main features of SSc, suggesting that Sema4A might be a novel therapeutic target in SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Carvalheiro T, Affandi AJ, Malvar-Fernández B, et al. Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis. Arthritis Rheumatol. 2019. PMID: 31012544. doi:10.1002/art.40915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。